The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Midazolam (Epistatus®) has been accepted for use in the treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years. This product provides a licensed alternative to unlicensed preparations.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
During October 2017 Clinical Knowledge Summaries were updated in the following areas.
The following topics were all reviewed:
The majority of topics have undergone reviews and minor restructures.
The most significant changes are in the Crohn's disease topic where recommendations on the diagnosis and management of confirmed Crohn's disease have been amended in line with current evidence, the sections on specialist investigations and management has been updated and expanded and the Prescribing information section has been deleted and links made to other relevant CKS topics. The Knee pain - assessment topic has been updated with new sections on risk factors and prognosis and the assessment and management recommendations have been amended in line with current evidence. Lastly, the Prostate cancer topic has been updated with recommendations on prostate-specific antigen (PSA) testing and treatments for prostate cancer amended in line with the latest guidance.
Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.